NO20044175L - Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser - Google Patents

Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser

Info

Publication number: NO20044175L
Authority: NO; Norway
Prior art keywords: epothilones; treatment; disease related; brain disease; proliferative processes
Prior art date: 2002-03-01

Application number

NO20044175A

Other languages

English (en)

Inventor

Ulrich Klar

Werner Skuballa

Bernd Buchmann

Jens Hoffmann

Rosemarie Lichtner

Andrea Rotgeri

Wolfgang Schwede

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-01

Filing date

2004-09-30

Publication date

2004-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27675676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044175(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-09-30 Application filed by Schering Ag filed Critical Schering Ag

2004-12-01 Publication of NO20044175L publication Critical patent/NO20044175L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20044175A 2002-03-01 2004-09-30 Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser NO20044175L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36106202P	2002-03-01	2002-03-01
EP02004745A EP1340498A1 (en)	2002-03-01	2002-03-01	Use of epothilones in the treatment of brain diseases associated with proliferative processes
PCT/EP2003/002085 WO2003074053A1 (en)	2002-03-01	2003-02-28	Use of epothilones in the treatment of brain diseases associated with proliferative processes

Publications (1)

Publication Number	Publication Date
NO20044175L true NO20044175L (no)	2004-12-01

Family

ID=27675676

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044175A NO20044175L (no)	2002-03-01	2004-09-30	Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser

Country Status (23)

Country	Link
US (1)	US20040019088A1 (no)
EP (2)	EP1340498A1 (no)
JP (1)	JP2005525360A (no)
KR (1)	KR20040095244A (no)
CN (1)	CN100473381C (no)
AR (1)	AR038712A1 (no)
AU (1)	AU2003215618B2 (no)
BR (1)	BR0308154A (no)
CA (1)	CA2477403A1 (no)
CR (1)	CR7444A (no)
EC (1)	ECSP045340A (no)
HK (1)	HK1079998A1 (no)
HR (1)	HRP20040892A2 (no)
IL (1)	IL163752A0 (no)
MX (1)	MXPA04008450A (no)
NO (1)	NO20044175L (no)
NZ (1)	NZ546617A (no)
PL (1)	PL370768A1 (no)
RU (1)	RU2351330C2 (no)
UA (1)	UA83798C2 (no)
WO (1)	WO2003074053A1 (no)
YU (1)	YU76404A (no)
ZA (1)	ZA200407905B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0977563B1 (en)	1996-12-03	2005-10-12	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2001512723A (ja) *	1997-08-09	2001-08-28	シエーリングアクチエンゲゼルシヤフト	新規エポチロン誘導体、その製法およびその薬学的使用
PL350190A1 (en) *	1999-02-11	2002-11-18	Schering Ag	Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
US7125893B1 (en) *	1999-04-30	2006-10-24	Schering Ag	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en)	2002-08-23	2004-03-04	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DE10331004A1 (de) *	2003-07-03	2005-02-24	Schering Ag	Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten
EP1559447A1 (en) *	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US20060069136A1 (en) *	2004-09-24	2006-03-30	Ulrich Klar	Use of Epothilones in the treatment of bone metastasis
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) *	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1700596A1 (en) *	2005-03-09	2006-09-13	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.	Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
DE102007016046A1 (de)	2007-03-30	2008-10-23	Bayer Schering Pharma Aktiengesellschaft	Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
MX2010011209A (es) *	2008-04-24	2010-11-12	Squibb Bristol Myers Co	Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
EP2793949B1 (en)	2011-12-23	2018-08-22	Innate Pharma	Enzymatic conjugation of antibodies
EP2872894B1 (en)	2012-07-13	2019-04-17	Innate Pharma	Screening of conjugated antibodies
EP2916872B1 (en)	2012-11-09	2019-02-27	Innate Pharma	Recognition tags for tgase-mediated conjugation
EP2968582B1 (en)	2013-03-15	2020-07-01	Innate Pharma	Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en)	2013-06-20	2014-12-24	Innate Pharma	Enzymatic conjugation of polypeptides
CA2914189C (en)	2013-06-21	2023-03-14	Innate Pharma	Enzymatic conjugation of polypeptides
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100400620B1 (ko) *	1995-06-09	2004-02-18	노파르티스 아게	라파마이신유도체
US6515016B2 (en) *	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) *	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
AU737621B2 (en) *	1997-02-18	2001-08-23	Canji, Inc.	Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
GB9801231D0 (en) *	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
JP2001512723A (ja) *	1997-08-09	2001-08-28	シエーリングアクチエンゲゼルシヤフト	新規エポチロン誘導体、その製法およびその薬学的使用
IL135590A (en) *	1997-12-04	2003-09-17	Bristol Myers Squibb Co	Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr) *	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) *	1998-02-25	2001-10-16	Novartis Ag	Cancer treatment with epothilones
WO1999067253A2 (en) *	1998-06-22	1999-12-29	Novartis Ag	Desmethyl epothilones
AU3156700A (en) *	1999-02-18	2000-09-04	Schering Aktiengesellschaft	16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
AR023792A1 (es) *	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
AU775373B2 (en) *	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DE10020517A1 (de) *	2000-04-19	2001-10-25	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) *	2000-05-26	2001-12-11	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
GB0013643D0 (en) *	2000-05-31	2000-07-26	Unilever Plc	Targeted moieties for use in bleach catalysts
WO2002098868A1 (en) *	2001-06-01	2002-12-12	Bristol-Myers Squibb Company	Epothilone derivatives

2002
- 2002-03-01 EP EP02004745A patent/EP1340498A1/en not_active Withdrawn
2003
- 2003-02-28 HR HRP20040892 patent/HRP20040892A2/hr not_active Application Discontinuation
- 2003-02-28 NZ NZ546617A patent/NZ546617A/en unknown
- 2003-02-28 KR KR10-2004-7013549A patent/KR20040095244A/ko not_active Ceased
- 2003-02-28 UA UA20040907817A patent/UA83798C2/ru unknown
- 2003-02-28 HK HK06100157.3A patent/HK1079998A1/zh unknown
- 2003-02-28 JP JP2003572570A patent/JP2005525360A/ja active Pending
- 2003-02-28 EP EP03743360A patent/EP1480643A1/en not_active Withdrawn
- 2003-02-28 AU AU2003215618A patent/AU2003215618B2/en not_active Expired - Fee Related
- 2003-02-28 BR BR0308154-0A patent/BR0308154A/pt not_active IP Right Cessation
- 2003-02-28 CN CNB038097613A patent/CN100473381C/zh not_active Expired - Fee Related
- 2003-02-28 CA CA002477403A patent/CA2477403A1/en not_active Abandoned
- 2003-02-28 RU RU2004129325/15A patent/RU2351330C2/ru active
- 2003-02-28 PL PL03370768A patent/PL370768A1/xx not_active Application Discontinuation
- 2003-02-28 IL IL16375203A patent/IL163752A0/xx unknown
- 2003-02-28 YU YU76404A patent/YU76404A/sh unknown
- 2003-02-28 US US10/375,043 patent/US20040019088A1/en not_active Abandoned
- 2003-02-28 WO PCT/EP2003/002085 patent/WO2003074053A1/en not_active Ceased
- 2003-02-28 MX MXPA04008450A patent/MXPA04008450A/es not_active Application Discontinuation
- 2003-03-03 AR ARP030100696A patent/AR038712A1/es unknown
2004
- 2004-09-01 CR CR7444A patent/CR7444A/es not_active Application Discontinuation
- 2004-09-30 ZA ZA200407905A patent/ZA200407905B/en unknown
- 2004-09-30 NO NO20044175A patent/NO20044175L/no not_active Application Discontinuation
- 2004-09-30 EC EC2004005340A patent/ECSP045340A/es unknown

Also Published As

Publication number	Publication date
RU2004129325A (ru)	2005-07-10
AR038712A1 (es)	2005-01-26
CR7444A (es)	2005-10-05
HK1079998A1 (zh)	2006-04-21
JP2005525360A (ja)	2005-08-25
BR0308154A (pt)	2005-01-04
CN100473381C (zh)	2009-04-01
PL370768A1 (en)	2005-05-30
CA2477403A1 (en)	2003-09-12
EP1340498A1 (en)	2003-09-03
HRP20040892A2 (en)	2004-12-31
NZ546617A (en)	2007-12-21
KR20040095244A (ko)	2004-11-12
YU76404A (sh)	2006-08-17
AU2003215618A1 (en)	2003-09-16
US20040019088A1 (en)	2004-01-29
MXPA04008450A (es)	2005-07-13
ECSP045340A (es)	2004-11-26
CN1649587A (zh)	2005-08-03
RU2351330C2 (ru)	2009-04-10
AU2003215618B2 (en)	2009-06-04
EP1480643A1 (en)	2004-12-01
IL163752A0 (en)	2005-12-18
ZA200407905B (en)	2006-04-26
UA83798C2 (ru)	2008-08-26
WO2003074053A1 (en)	2003-09-12

Publication	Publication Date	Title
NO20044175L (no)	2004-12-01	Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser
CY2015025I1 (el)	2016-04-13	Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
ATE550338T1 (de)	2012-04-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602006019838D1 (de)	2011-03-10	Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE440866T1 (de)	2009-09-15	Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
SI1706112T1 (sl)	2014-07-31	Postopki za zdravljenje vnetne bolezni
DE602005007717D1 (de)	2008-08-07	Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ES2414872T8 (es)	2014-11-06	Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
GB0329874D0 (en)	2004-01-28	Compounds useful for the treatment of diseases
CY2018006I2 (el)	2018-06-27	Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
FI20020479A7 (fi)	2003-09-15	Pintakäsittelyprosessi
PL1685125T3 (pl)	2012-10-31	Pochodne pirrolowe użyteczne do leczenia chorób proliferacyjnych
ATE443704T1 (de)	2009-10-15	Pyridopyrimidinone zur behandlung von krebserkrankungen
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
EP1812077A4 (en)	2009-12-02	MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
EP1855679A4 (en)	2014-07-23	AMINOMETHYL-BETA-SEKRETASE-INHIBITOR FOR THE TREATMENT OF ALZHEIMER
PT1828151E (pt)	2011-06-16	Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer
IL184849A0 (en)	2007-12-03	Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
NO20055820D0 (no)	2005-12-08	Peptider til anvendelse ved behandling av overvekt
PT1881824E (pt)	2015-03-26	Utilização de triglicéridos docosaexaenóicos para o tratamento de doenças tumorais
NO20043674L (no)	2004-10-06	Fremgangsmate for behandling av karbonholdige stoffer
ATE439843T1 (de)	2009-09-15	S-mirtazapin zur behandlung von hitzewallungen
FR2855050B1 (fr)	2008-07-04	Procede de traitement cosmetique des rougeurs
GB0400802D0 (en)	2004-02-18	Compounds for the treatment of disease
PL1904060T3 (pl)	2011-12-30	Zastosowanie pochodnych ftalocyjaniny do nie-fotodynamicznego leczenia chorób

Legal Events

Date	Code	Title	Description
2010-09-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application